Exodus Point Capital Management, LP Phathom Pharmaceuticals, Inc. Transaction History
Exodus Point Capital Management, LP
- $16.4 Billion
- Q3 2024
A detailed history of Exodus Point Capital Management, LP transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Exodus Point Capital Management, LP holds 69,282 shares of PHAT stock, worth $527,236. This represents 0.01% of its overall portfolio holdings.
Number of Shares
69,282Holding current value
$527,236% of portfolio
0.01%Shares
6 transactions
Others Institutions Holding PHAT
# of Institutions
144Shares Held
73.6MCall Options Held
42.3KPut Options Held
45.7K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$76.9 Million9.84% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$56.8 Million28.04% of portfolio
-
Jennison Associates LLC5.87MShares$44.6 Million0.07% of portfolio
-
Invesco Ltd. Atlanta, GA4.1MShares$31.2 Million0.01% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$26.6 Million9.52% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $298M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...